Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Archer (ACHR) is upgraded to speculative Buy amid new revenue streams, strong balance sheet, and attractive valuation. See if ...

Not every company will or should climb the AI maturity ladder at the same speed. Enterprises with scale must move deliberately, testing and tightening before rolling out company-wide. Leaner teams win ...

Each year IPWatchdog surveys the IP community to get their thoughts on what the biggest moments in IP were that year. Some ...

With a new year upon us, software-security experts disagree on SBOM utility — in theory, SBOMs are great, but in practice, ...

Brexit has not only intensified Britain’s weaknesses; its third major cost has been to dull one of the country’s strengths.

Schuster Law has announced the release of an updated informational briefing on recent trends and procedural requirements in ...

FROM THE WILDERNESS: With less than a week left until the new year, Democrats are trying to plot a path out of the wilderness through the midterms. It’s been more than 365 days of infighting and big ...

Heisman runner-up Diego Pavia is playing against Iowa in the ReliaQuest Bowl. That alone makes Vanderbilt vs. Iowa must-watch ...

Colorectal cancer breaks the usual immune rules, with certain regulatory T cells linked to improved survival. In many solid ...

The need to move beyond 12 V in automotive systems has been apparent for years, but now, finally, consensus seems to have ...

From global icons to unheard journeys, Sportstar’s 2025 reporting looked beyond the scoreboard — placing performance within ...